A related party has reached a definitive agreement with Cosmos Health Inc., a Chicago-based diversified, vertically integrated global healthcare group that engages in innovative research and development, owns proprietary pharmaceutical and...
Wainua (eplontersen) from AstraZeneca and Ionis has been licensed in the United States for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults, also known as hATTR-PN or ATTRv-PN. Wainua is the only licensed...
The domestic pharmaceutical industry anticipates another year of continuous growth in 2024, despite a number of hurdles, such as maintaining quality standards while transitioning from volume to value leadership. To satisfy the increasing...
Ono Pharmaceutical Co., Ltd announced a discovery collaboration agreement with EVQLV, INC to create novel antibodies against diverse targets chosen by Ono for the development of novel antibody medicines. Under the agreement, EVQLV will generate...
Aptar Digital Health, a global leader in software as a medical device (SaMD), digital Patient Support Programmes (PSPs), and disease management solutions, has announced a new collaboration with Legit.Health, a cutting-edge artificial intelligence...
As per AstraZeneca Pharma India Limited, Trastuzumab Deruxtecan, also known as Enhertu, will be accessible in January 2024 for the treatment of HER2-positive breast cancer. The company received clearance from the Central Drugs Standard Control...
The Research Council of Norway has awarded NOK 16 million to Hemispherian AS, an Oslo-based Norwegian preclinical pharmaceutical business concentrating on small molecule cancer therapies. Hemispherian's GLIX patented chemicals target a unique...
Owkin, a French-American biotechnology company that uses artificial intelligence (AI) in drug discovery and development as well as diagnostics, announced a collaboration agreement with MSD, the trade name of Merck & Co Inc, to develop and...
Gilead Sciences, Inc has announced an exclusive license deal with Compugen Ltd. to license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, which includes the COM503 drug candidate. Compugen Ltd. is a...
Chugai Pharmaceutical Co., Ltd. announced its plan to invest in their Bio drug substance (DS) manufacturing facility "UK3" at Chugai Pharma Manufacturing Co., Ltd.'s Ukima Plant (Kita-ku, Tokyo). UK3 includes DS production for phase 3 clinical...
, CDSCO.jpg)
